Toggle Main Menu Toggle Search

Open Access padlockePrints

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers

Lookup NU author(s): Professor Ruth Plummer, Dr Louise Li, Rebecca Perrett, Professor Alan Calvert


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Purpose: To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of lexatumumab (HGS-ETR2), a fully human agonistic monoclonal antibody which targets and activates the tumor necrosis factor - related apoptosis-inducing ligand receptor 2 (TRAIL-R2) in patients with advanced solid malignancies. Experimental Design: In this phase1, open label study, patients with advanced solid malignancies were treated with escalating doses of lexatumumab administered i.v. over 30 to 120 min every 21 days. A cohort of four patients, which could be expanded to six patients, was studied at each dose level. The dose-limiting toxicity (DLT) dose was defined as the dose at which the incidence of DLT in the first two cycles was ≥33%. The maximum tolerated dose was defined as the highest dose at which <33% of subjects experienced DLT. The pharmacokinetics and immunogenicity of lexatumumab were also characterized. Tumor specimens from historical or current biopsies, when available, were stained for TRAIL-R2 using immunohistochemistry techniques. Results: Thirty-seven patients received 120 cycles of lexatumumab at doses ranging from 0.1 to 20 mg/kg every 21 days as of May 2006. The 20 mg/kg dose was identified as the DLT dose based on DLTs in three of seven patients treated with this dose; DLTs included asymptomatic elevations of serum amylase, transaminases, and bilirubin. The 10 mg/kg dose cohort was expanded to 12 patients and the 10 mg/kg dose was identified as the maximum tolerated dose. The mean (±SD) clearance and apparent terminal half-life values at the 10 mg/kg dose averaged 6.0 (2.9) mL/d/kg and 16.4 (10.9) days, respectively. Twelve patients had durable stable disease that lasted a median of 4.5 months, including three patients with sarcoma having prolonged stable disease (≥6.7 months). Immunohistochemistry for TRAIL-R2 showed specific staining in >10% of tumor cells for 16 of the 20 evaluable specimens submitted (80%). Conclusions: Lexatumumab was safe and well tolerated at doses up to and including 10 mg/kg every 21 days. Lexatumumab was associated with sustained stable disease in several patients. Pharmacokinetics were linear over the dose range studied, and consistent with a two-compartment model with first-order elimination from the central compartment. Additional evaluation of this novel apoptosis-inducing agent, particularly in combination with chemotherapy agents, is warranted and ongoing. ©2007 American Association for Cancer Research.

Publication metadata

Author(s): Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett RH, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert AH, de Bono J

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 2007

Volume: 13

Issue: 20

Pages: 6187-6194

Print publication date: 15/10/2007

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265


DOI: 10.1158/1078-0432.CCR-07-0950

PubMed id: 17947486


Altmetrics provided by Altmetric


Funder referenceFunder name
G0501019Medical Research Council